Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods.
about
Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug developmentQuality assessment of digital annotated ECG data from clinical trials by the FDA ECG Warehouse.Quantitative performance of E-Scribe warehouse in detecting quality issues with digital annotated ECG data from healthy subjects.QT/QTc prolongation in placebo-treated subjects: a PhRMA collaborative data analysis.The effect of moxifloxacin on QTc and implications for the design of thorough QT studies.Reference regions for beat-to-beat ECG data.The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.Contrasting time- and rate-based approaches for the assessment of drug-induced QT changes.A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.Static and Dynamic Electrocardiographic Patterns Preceding Torsades de Pointes in the Acquired and Congenital Long QT SyndromeAre women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalolICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies.Measurement and regulation of cardiac ventricular repolarization: from the QT interval to repolarization morphology.Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?Comparison of Digital 12-Lead ECG and Digital 12-Lead Holter ECG Recordings in Healthy Male Subjects: Results from a Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Magnitude, mechanism, and reproducibility of QT interval differences between superimposed global and individual lead ECG complexes.Impaired T-amplitude adaptation to heart rate characterizes I(Kr) inhibition in the congenital and acquired forms of the long QT syndrome.ECG-based estimation of dispersion of APD restitution as a tool to stratify sotalol-induced arrhythmic risk.Issues in QT interval measurement.Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization.Comparison of semiautomated and fully automated methods for QT measurement during a thorough QT/QTc study: variability and sample size considerations.Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry.Man versus machine: is there an optimal method for QT measurements in thorough QT studies?Minimal T-wave representation and its use in the assessment of drug arrhythmogenicity.Computerized extraction of electrocardiograms from continuous 12-lead holter recordings reduces measurement variability in a thorough QT study.Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes.Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
P2860
Q24646866-2C3C18B6-4E79-4AEA-91BB-16A87589B9C8Q31129877-6D383513-AE18-4520-A8C1-7ADB68203C7EQ31150161-B08D550A-4589-453C-8543-4B2D46ADCAFEQ31155117-693C8E60-F646-47F4-A820-FE1AF0BFC626Q33411837-3D1F1E85-B6BB-417D-A996-0050E6C0B7B1Q33612468-07AA9345-5799-47F2-BC42-9E41F860FD01Q33661017-3F9C5D41-DBC7-4602-B6D6-F7E5601E3084Q34656447-8AD45D07-A86B-4B02-A969-8BD22CDB309BQ34724614-05F45C38-741F-401A-9BA0-224637C6FE35Q35071459-ED669978-7613-4624-9609-19C0AD44AE23Q35211438-01C1D6A3-0432-441D-89D6-94BF5322279EQ36729914-B407ACC8-5C70-4FFA-BEB6-E4FACEEFE8A9Q37082975-9FA5E2B4-D546-4D66-A632-0D940EB2DACFQ38082420-6CF19A8B-C3C7-4914-A1DF-C3D2026232B5Q39251845-9903C1C7-F1F8-443B-991E-C79AD97326BFQ39802290-0F6054EC-C2C1-41C2-B239-E480B6E3C2FCQ39816260-14185E0E-A342-4453-9A81-01C08AFBF3DFQ41209529-C2746A63-27BF-4B62-9944-2E2885FAD266Q42337268-2C6E1FF7-1250-4217-B719-7C824410A679Q43059195-FD9972D7-0568-41A4-83AB-A550A7E85AFFQ45960668-BE3CD831-2809-480B-84F1-4C9EDCE7E002Q46090429-892F7301-BC4E-4ED7-881C-499D354CEA97Q46502909-ADBE7F1B-B83A-4192-A03A-28D53DD2D9CBQ47337001-CED5F401-EF72-46C8-AC65-46667B09C5BDQ50559385-1A44B018-0887-425F-8A6A-B623AE9D9713Q51467512-563A1EE6-2588-48A0-A951-EF0894A624E7Q52590590-691574B4-F809-4A33-B1FA-EF5B1F3756E7Q53256610-F9AC4EED-811B-4977-A29F-5EAA5F42195C
P2860
Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Electrocardiographic identific ...... rding and measurement methods.
@en
Electrocardiographic identific ...... rding and measurement methods.
@nl
type
label
Electrocardiographic identific ...... rding and measurement methods.
@en
Electrocardiographic identific ...... rding and measurement methods.
@nl
prefLabel
Electrocardiographic identific ...... rding and measurement methods.
@en
Electrocardiographic identific ...... rding and measurement methods.
@nl
P2093
P2860
P1476
Electrocardiographic identific ...... ording and measurement methods
@en
P2093
Arthur J Moss
Borje Darpo
Janet D McEnroe
Jean-Philippe Couderc
Joel Morganroth
Joseph C Fleishaker
Nenad Sarapa
Steven F Francom
William T Chen
Wojciech Zareba
P2860
P356
10.1111/J.1542-474X.2004.91546.X
P577
2004-01-01T00:00:00Z